Taysha Gene Therapies Presents Promising TSHA-102 Data

Taysha Gene Therapies ( (TSHA) ) just unveiled an announcement.

On October 9, 2025, Taysha Gene Therapies presented new supplemental data from Part A of the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome at the 54th CNS Annual Meeting. The analysis showed 100% of patients achieved developmental milestones and additional skill gains, reinforcing TSHA-102’s potential impact on activities of daily living. This suggests a broad and consistent therapeutic effect across core domains of Rett syndrome, which could significantly influence treatment approaches and improve patient and caregiver experiences.

The most recent analyst rating on (TSHA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.

Spark’s Take on TSHA Stock

According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.

Taysha Gene Therapies’ stock score is primarily influenced by its challenging financial performance, despite strong technical momentum and positive earnings call highlights. The company’s ongoing financial losses and cash flow issues weigh heavily on the score, though clinical progress and regulatory achievements provide a positive outlook.

To see Spark’s full report on TSHA stock, click here.

More about Taysha Gene Therapies

Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.

Average Trading Volume: 5,726,672

Technical Sentiment Signal: Buy

Current Market Cap: $1.29B

See more data about TSHA stock on TipRanks’ Stock Analysis page.